Abu Dhabi Health Department Signs MoU with Xlife Sciences to Boost Life-Sciences Sector

By HEOR Staff Writer

September 12, 2023

The Department of Health – Abu Dhabi (DoH) and Swiss firm Xlife Sciences have signed a Memorandum of Understanding (MoU) in a bid to fortify the Emirate’s life-sciences sector. The agreement, which was signed at the Department’s Headquarters, aims to enhance innovation, funding opportunities for life sciences start-ups, and clinical research within the Emirate.

The collaboration is part of DoH’s ongoing efforts to establish Abu Dhabi as a global hub for healthcare and life sciences. It will provide incubation training, mentoring, and commercialisation support to innovators, while also exploring the possibility of a joint funding framework with local ecosystem partners.

Dr. Asma Ibrahim Al Mannaei, Executive Director of Research and Innovation Centre at the DoH, expressed her delight at the collaboration, citing it as a step towards addressing global healthcare challenges and reinforcing the development of Abu Dhabi’s life sciences sector.

Xlife Sciences, represented by CEO Oliver R. Baumann, has established their UAE presence through a partnership with ICEBERG Capital, a company based in Abu Dhabi Global Market (ADGM) and regulated by Financial Services Regulatory Authority (FSRA). ICEBERG Capital will be handling the company’s investment strategy and fund management, further enhancing the life sciences ecosystem in Abu Dhabi.

Abdullah Al Weshah, Managing Director – ICEBERG Capital, commented on the collaboration, expressing excitement at the prospect of supporting the Abu Dhabi Life-Sciences ecosystem and looking forward to establishing a joint funding framework to support start-ups, founders, and projects.

This agreement further cements Abu Dhabi’s position as a global life sciences hub and an incubator for healthcare innovation, while spearheading the transformation of the regional healthcare ecosystem through leveraging sciences and technology. 

Reference url

Recent Posts

Pharmaceutical Onshoring Agreements: Navigating Tariff Relief and National Security Policies

By João L. Carapinha

May 18, 2026

The US Bureau of Industry and Security published formal procedures enabling manufacturers of patented pharmaceutical products to apply for company-specific pharmaceutical onshoring agreements with the Department of Commerce. These agreements allow qualifying firms to secure a reduced Section 232 ...
Dynamic Risk Stratification in Thromboembolism Prevention for Cancer Patients
Dynamic risk stratification enables more precise forecasting of venous thromboembolism risk in cancer patients by continuously updating predictions as new clinical data emerge. A transformer-based deep learning model was developed using longitudinal electronic health records from the U.S. Veteran...
Core Recommendations for Equitable Digital Medicine Access
Ensuring equitable digital medicine access stands as a central goal of the Council of Europe’s latest guidance on remote pharmaceutical services. The CM...